Maintaining an average hydroxychloroquine whole blood level above 1,068 ng/mL significantly reduced the risk of thrombosis in adults with systemic lupus.
This means that zinc, low dose HCQ, and azithromycin and may prevent a large number of hospitalizations and probably deaths during the SARS-CoV-2 pandemic.
HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 115 studies to date is estimated to be 1 in 20 million (p = 0.000000049).
This study of critically ill patients with laboratory-confirmed COVID-19 admitted to ICUs in Mexico demonstrated that age and CRP levels upon ICU admission were associated with in-hospital mortality
The aim of this study is to describe the characteristics and impact of different therapies on clinical outcomes in a cohort of severe COVID-19 patients.
In our study, we found hydroxychloroquine wasn’t associated with significant arrhythmia clearly relating to hydroxychloroquine so it seemed the drug was very, very safe
Use of chloroquine (tablets) is showing favorable outcomes in humans infected with Coronavirus including faster time to recovery and shorter hospital stay.
HCQ use significantly reduced the mortality rate, but this association was found only in the lowest cumulative dosage exposure group.
Our data suggest that chronic treatment with HCQ confer protection against SARS-CoV-2 infection.
No life-threatening modifications of the QT interval was observed in non-severe COVID-19 patients treated ambulatory with hydroxychloroquine and azithromycin. Studies are needed in critical-ill and older patients.
The clinical trials on this list are studying Hydroxychloroquine. All trials on the list are supported by NCI.
This study provides evidence that (hydroxy)chloroquine may be used effectively in treating moderate COVID-19 and supports larger trials.
Conclusions: In subjects free of COVID-19, we found a small increase in QTc associated with use of chloroquine, but not hydroxychloroquine. We found no increased mortality associated with use of hydroxychloroquine.
All it took for a safe, generic drug — listed for decades by the World Health Organization (WHO) as one of the drugs that should be immediately and universally available worldwide at all times — to be considered dangerous, was for President Trump to say “I happen to feel good about it.”
None of the patients died in the studied period and only 6 have to be admitted in conventional hospitalization area.
To increase the effectiveness of treatments and results, researchers need to give greater focus, when designing trials and when extrapolating from them.
Here, we summarize the results or design of clinical studies recently completed or initiated to evaluate the therapeutic activity of chloroquine derivatives in cancer patients.
